StockData
AbbVie Inc. logo

AbbVie Inc. (ABBV) operating KPIs

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)

Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%

AbbVie research and development expense ($M) ($M)

Form 10-Q / 10-K

QuarterlyAnnual
Latest, FY2025
9,096
Period ended Dec 31, 2025
Change on a year earlier
-28.9%
12,791 in FY2024
History
15 years
Since FY2011
Sources
9
Documents cited below

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedResearch and development expense ($M) ($M)Year on yearSource
FY2025Dec 31, 20259,096-28.9%Form 10-K (filed 2026-02-20) ↗
FY2024Dec 31, 202412,791+66.7%Form 10-K (filed 2025-02-14) ↗
FY2023Dec 31, 20237,675+17.9%Form 10-K (filed 2024-02-20) ↗
FY2022Dec 31, 20226,510-6.0%Form 10-K (filed 2023-02-17) ↗
FY2021Dec 31, 20216,922+8.5%Form 10-K (filed 2023-02-17) ↗
FY2020Dec 31, 20206,379-0.4%Form 10-K (filed 2023-02-17) ↗
FY2019Dec 31, 20196,407-38.0%Form 10-K (filed 2020-02-21) ↗
FY2018Dec 31, 201810,329+106.3%Form 10-K (filed 2019-02-27) ↗
FY2017Dec 31, 20175,007+14.2%Form 10-K (filed 2019-02-27) ↗
FY2016Dec 31, 20164,385+2.3%Form 10-K (filed 2019-02-27) ↗
FY2015Dec 31, 20154,285+30.0%Form 10-K (filed 2016-02-19) ↗
FY2014Dec 31, 20143,297+15.5%Form 10-K (filed 2015-02-20) ↗
FY2013Dec 31, 20132,855+2.8%Form 10-K (filed 2014-02-21) ↗
FY2012Dec 31, 20122,778+6.1%Form 10-K (filed 2014-02-21) ↗
FY2011Dec 31, 20112,618–Form 10-K (filed 2014-02-21) ↗

Cite this data

StockData. (2026). AbbVie Research and development expense ($M) ($M), annual FY2011–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/fs_rd

See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.